Pfizer and Moderna are both trying to recover from declining COVID vaccine sales, but they offer pretty different risk profiles right now. Moderna is up 69% in the last three months mostly due to solid phase 2 data for an mRNA cancer vaccine they're working on with Merck. At a $22B market cap, they have higher upside but also carry a lot more risk. If their pending flu vaccine gets denied by the FDA or their phase 3 cancer trials fail, the stock will likely take a big hit. Pfizer is sitting at a $156B market cap with over $60B in annual revenue. They are facing some patent cliffs soon, including Eliquis, but they have the cash to buy out competitors to fill those pipeline gaps. They recently acquired a promising weight loss drug called MET-097i. They are definitely the safer play and currently have a 6.3% dividend yield. Basically, Moderna is the play for higher risk and potential upside, while Pfizer is better for stable blue-chip dividends.